Skip to main content
SpringerLink
Log in

Targeting Inflammatory Pathways in Epithelial Ovarian Cancer

  • Chapter
  • First Online:
Emerging Therapeutic Targets in Ovarian Cancer

  • 543 Accesses

Abstract

Platinum and taxane regimes remain the cornerstone of chemotherapeutic management in epithelial ovarian cancer (EOC). As most patients relapse after first-line therapy, attempts at improving survival rates in this setting by combining standard treatment with other cytotoxic agents have only had limited success. In platinum-resistant/refractory disease, single agents have modest activity with an average response rate of 20%. As it appears that a therapeutic ceiling has been reached with chemotherapy, there is a need to adopt novel approaches that incorporate the targeting of mechanisms underpinning processes in the EOC microenvironment related to proliferation, survival, metastatic development and platinum resistance. There is growing evidence that inflammatory pathways are integral to such processes and this chapter focuses upon the effects and potential benefits observed with targeting key inflammatory mediators in EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Acheson ED, Gardner MJ, Pippard EC, Grime LP (1982). Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40-year follow-up. Br J Ind Med 39:344–48.

    PubMed  CAS  Google Scholar 

  • Altinoz MA, Korkmaz R (2004). NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 51:239–47.

    PubMed  CAS  Google Scholar 

  • Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR (2004). Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902–10.

    PubMed  CAS  Google Scholar 

  • Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255–88.

    PubMed  CAS  Google Scholar 

  • Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R (1991). Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 67:990–96.

    PubMed  CAS  Google Scholar 

  • Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4:540–50.

    PubMed  CAS  Google Scholar 

  • Balkwill F (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25:409–16.

    PubMed  CAS  Google Scholar 

  • Balkwill F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9:361–71.

    PubMed  CAS  Google Scholar 

  • Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357:539–45.

    PubMed  CAS  Google Scholar 

  • Borsellino N, Belldegrun A, Bonavida B (1995). Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55:4633–39.

    PubMed  CAS  Google Scholar 

  • Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D‘Alessandro N (1999). Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85:134–44.

    PubMed  CAS  Google Scholar 

  • Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A (1997). Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572–79.

    PubMed  CAS  Google Scholar 

  • Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–64.

    PubMed  CAS  Google Scholar 

  • Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995). Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–22.

    PubMed  CAS  Google Scholar 

  • Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, Dewitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer. Ann Oncol 19(7):1340–46.

    PubMed  CAS  Google Scholar 

  • Burger JA, Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761–67.

    PubMed  CAS  Google Scholar 

  • Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, Lin J (2001). Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 20:7925–34.

    PubMed  CAS  Google Scholar 

  • Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF (2000). A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 6:851–60.

    PubMed  CAS  Google Scholar 

  • Cabillic F, Bouet-Toussaint F, Toutirais O, Rioux-Leclercq N, Fergelot P, de la Pintiere CT, Genetet N, Patard JJ, Catros-Quemener V (2006). Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte–dendritic cell cross-talk. Clin Exp Immunol 146:518–23.

    PubMed  CAS  Google Scholar 

  • Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP (2000). Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164–70.

    PubMed  CAS  Google Scholar 

  • Carreiras F, Thiebot B, Leroy-Dudal J, Maubant S, Breton MF, Darbeida H (2002). Involvement of alphavbeta 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line IGROV1 on the human umbilical vein cell extracellular matrix. Int J Cancer 99:800–08.

    PubMed  CAS  Google Scholar 

  • Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–70.

    PubMed  CAS  Google Scholar 

  • Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML (1997). Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3:999–1007.

    PubMed  CAS  Google Scholar 

  • Chambers SK, Wang Y, Gertz RE, Kacinski BM (1995). Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 55:1578–85.

    PubMed  CAS  Google Scholar 

  • Chammas R, Brentani R (1991). Integrins and metastases: an overview. Tumour Biol 12:309–20.

    PubMed  CAS  Google Scholar 

  • Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ (1999). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59:991–94.

    PubMed  CAS  Google Scholar 

  • Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T (2009). The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119(10):3011–23.

    PubMed  CAS  Google Scholar 

  • Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI (2004). CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 65:906–16.

    PubMed  CAS  Google Scholar 

  • Combates NJ, Rzepka RW, Chen YN, Cohen D (1994). NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269:29715–19.

    PubMed  CAS  Google Scholar 

  • Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M (2001). Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61:8851–58.

    PubMed  CAS  Google Scholar 

  • Cook LS, Kamb ML, Weiss NS (1997). Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 145:459–65.

    PubMed  CAS  Google Scholar 

  • Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420:860–67.

    PubMed  CAS  Google Scholar 

  • Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA, Harlow BL (1999). Genital talc exposure and risk of ovarian cancer. Int J Cancer 81:351–56.

    PubMed  CAS  Google Scholar 

  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–49.

    PubMed  CAS  Google Scholar 

  • Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–07.

    PubMed  CAS  Google Scholar 

  • D‘Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–85.

    PubMed  Google Scholar 

  • Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope CG, Risberg B, Kopolovic J (2003). AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90:248–57.

    PubMed  CAS  Google Scholar 

  • Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893–903.

    PubMed  CAS  Google Scholar 

  • Denkert C, Koch I, Berger S, Kobel M, Siegert A, Hauptmann S (2003). Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. Cancer Lett 195:101–09.

    PubMed  CAS  Google Scholar 

  • Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, et al. (1995). Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406–09.

    PubMed  CAS  Google Scholar 

  • Dobrovolskaia MA, Kozlov SV (2005). Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 5:325–44.

    PubMed  CAS  Google Scholar 

  • Downs LS Jr., Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF (2008). A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 112:331–39.

    PubMed  CAS  Google Scholar 

  • Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999). Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445–53.

    PubMed  CAS  Google Scholar 

  • Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV (2006). Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12:5055–63.

    PubMed  CAS  Google Scholar 

  • Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA (2004). Thalidomide in cancer medicine. Ann Oncol 15:1151–60.

    PubMed  CAS  Google Scholar 

  • Espey LL (1994). Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 50:233–38.

    PubMed  CAS  Google Scholar 

  • Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O‘Brien S, Albitar M (2002). The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100:1215–19.

    PubMed  CAS  Google Scholar 

  • Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002). Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205–11.

    PubMed  CAS  Google Scholar 

  • Galban S, Fan J, Martindale JL, Cheadle C, Hoffman B, Woods MP, Temeles G, Brieger J, Decker J, Gorospe M (2003). von Hippel–Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol Cell Biol 23:2316–28.

    PubMed  CAS  Google Scholar 

  • Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, Hankinson SE (2000). Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 92:249–52.

    PubMed  CAS  Google Scholar 

  • Graham J, Graham R (1967). Ovarian cancer and asbestos. Environ Res 1:115–28.

    PubMed  CAS  Google Scholar 

  • Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–96.

    PubMed  CAS  Google Scholar 

  • Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM (2006). Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 106:1776–84.

    PubMed  CAS  Google Scholar 

  • Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y, Ma W, Hu H, Liu Y (2007). The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces 60:1–6.

    PubMed  CAS  Google Scholar 

  • Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR (2007). Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 6:1993–2002.

    PubMed  CAS  Google Scholar 

  • Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176:5023–32.

    PubMed  CAS  Google Scholar 

  • Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175:1197–205.

    PubMed  CAS  Google Scholar 

  • Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M, Reuning U (2003). Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/vitronectin interaction. Biol Chem 384:1073–83.

    PubMed  CAS  Google Scholar 

  • Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:1123–32.

    PubMed  CAS  Google Scholar 

  • Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13:559–83.

    PubMed  CAS  Google Scholar 

  • Heaps JM, Nieberg RK, Berek JS (1990). Malignant neoplasms arising in endometriosis. Obstet Gynecol 75:1023–28.

    PubMed  CAS  Google Scholar 

  • Hodge DR, Hurt EM, Farrar WL (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41:2502–12.

    PubMed  CAS  Google Scholar 

  • Hodge-Dufour J, Marino MW, Horton MR, Jungbluth A, Burdick MD, Strieter RM, Noble PW, Hunter CA, Pure E (1998). Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci USA 95:13806–11.

    PubMed  CAS  Google Scholar 

  • Huang M, Page C, Reynolds RK, Lin J (2000a). Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79:67–73.

    PubMed  CAS  Google Scholar 

  • Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ (2000b). Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334–39.

    PubMed  CAS  Google Scholar 

  • Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brannstrom M (1998). The chemotactic cytokine interleukin-8 – a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 71:420–23.

    PubMed  CAS  Google Scholar 

  • Kacinski BM, Carter D, Kohorn EI, Mittal K, Bloodgood RS, Donahue J, Kramer CA, Fischer D, Edwards R, Chambers SK, et al. (1989). Oncogene expression in vivo by ovarian adenocarcinomas and mixed-Mullerian tumors. Yale J Biol Med 62:379–92.

    PubMed  CAS  Google Scholar 

  • Kacinski BM, Carter D, Mittal K, Yee LD, Scata KA, Donofrio L, Chambers SK, Wang KI, Yang-Feng T, Rohrschneider LR, et al. (1990). Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 137:135–47.

    PubMed  CAS  Google Scholar 

  • Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F (2008). Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122:91–99.

    PubMed  CAS  Google Scholar 

  • Kallunki T, Deng T, Hibi M, Karin M (1996). c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87:929–39.

    PubMed  CAS  Google Scholar 

  • Karin M, Cao Y, Greten FR, Li ZW (2002). NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–10.

    PubMed  CAS  Google Scholar 

  • Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T (2001). Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282:735–38.

    PubMed  CAS  Google Scholar 

  • Kishimoto T, Taga T, Yamasaki K, Matsuda T, Tang B, Muraguchi A, Horii Y, Suematsu S, Hirata Y, Yawata H, et al. (1989). Normal and abnormal regulation of human B cell differentiation by a new cytokine, BSF2/IL-6. Adv Exp Med Biol 254:135–43.

    PubMed  CAS  Google Scholar 

  • Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798–801.

    PubMed  CAS  Google Scholar 

  • Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M (1999). Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29:688–96.

    PubMed  CAS  Google Scholar 

  • Kolls JK, Linden A (2004). Interleukin-17 family members and inflammation. Immunity 21:467–76.

    PubMed  CAS  Google Scholar 

  • Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W (2007). Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178:6730–33.

    PubMed  CAS  Google Scholar 

  • Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F (2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67:585–92.

    PubMed  CAS  Google Scholar 

  • Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC (2009a). Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11:529–41.

    PubMed  CAS  Google Scholar 

  • Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F (2009b). An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 8:1893–905.

    PubMed  CAS  Google Scholar 

  • Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK (2008). Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10:1259–67.

    PubMed  CAS  Google Scholar 

  • Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006). IL-23 promotes tumour incidence and growth. Nature 442:461–65.

    PubMed  CAS  Google Scholar 

  • Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R, Gauduchon P, Carreiras F (2005). Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer 114:531–43.

    PubMed  CAS  Google Scholar 

  • Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–19.

    PubMed  CAS  Google Scholar 

  • Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:459–69.

    PubMed  CAS  Google Scholar 

  • Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC Jr. (1993). Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 207:332–39.

    PubMed  CAS  Google Scholar 

  • Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–60.

    PubMed  CAS  Google Scholar 

  • Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK (1997). Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91:197–208.

    PubMed  CAS  Google Scholar 

  • Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK (2007). Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13:3423–30.

    PubMed  CAS  Google Scholar 

  • Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–61.

    PubMed  CAS  Google Scholar 

  • Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA (1999). Synergy between an antiangiogenic integrin alphav antagonist and an antibody–cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 96:1591–96.

    PubMed  CAS  Google Scholar 

  • Lossner D, Abou-Ajram C, Benge A, Reuning U (2008). Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int J Biochem Cell Biol 40:2746–61.

    PubMed  Google Scholar 

  • Lotem J, Sachs L (1992). Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750–57.

    PubMed  CAS  Google Scholar 

  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266:807–10.

    PubMed  CAS  Google Scholar 

  • Lu H, Ouyang W, Huang C (2006). Inflammation, a key event in cancer development. Mol Cancer Res 4:221–33.

    PubMed  Google Scholar 

  • Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A (1999). Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59:4681–87.

    PubMed  CAS  Google Scholar 

  • Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151:1105–13.

    PubMed  CAS  Google Scholar 

  • Lundin E, Dossus L, Clendenen T, Krogh V, Grankvist K, Wulff M, Sieri S, Arslan AA, Lenner P, Berrino F, Hallmans G, Zeleniuch-Jacquotte A, Toniolo P, Lukanova A (2009). C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 20(7):1151–59.

    PubMed  Google Scholar 

  • Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G (2005). Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106:362–67.

    PubMed  CAS  Google Scholar 

  • Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS (2005). Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23:5950–59.

    PubMed  CAS  Google Scholar 

  • Maiuri MC, Tajana G, Iuvone T, De Stefano D, Mele G, Ribecco MT, Cinelli MP, Romano MF, Turco MC, Carnuccio R (2004). Nuclear factor-kappa B regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model. Am J Pathol 165:115–26.

    PubMed  CAS  Google Scholar 

  • Makinoda S, Hirosaki N, Waseda T, Tomizawa H, Fujii R (2008). Granulocyte colony-stimulating factor (G-CSF) in the mechanism of human ovulation and its clinical usefulness. Curr Med Chem 15:604–13.

    PubMed  CAS  Google Scholar 

  • Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature 454:436–44.

    PubMed  CAS  Google Scholar 

  • Markland FS, Shieh K, Zhou Q, Golubkov V, Sherwin RP, Richters V, Sposto R (2001). A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model. Haemostasis 31:183–91.

    PubMed  CAS  Google Scholar 

  • Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G (1996). Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67:826–30.

    PubMed  CAS  Google Scholar 

  • Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, Staedel C, Gauduchon P (2002). Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 97:186–94.

    PubMed  CAS  Google Scholar 

  • McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ (2007). C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109:933–41.

    PubMed  CAS  Google Scholar 

  • Merritt MA, Green AC, Nagle CM, Webb PM (2008a). Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–76.

    PubMed  CAS  Google Scholar 

  • Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK (2008b). Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100:359–72.

    PubMed  CAS  Google Scholar 

  • Michalaki V, Syrigos K, Charles P, Waxman J (2004). Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90:2312–16.

    PubMed  CAS  Google Scholar 

  • Milliken D, Scotton C, Raju S, Balkwill F, Wilson J (2002). Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 8:1108–14.

    PubMed  CAS  Google Scholar 

  • Mitchell RA (2004). Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16:13–19.

    PubMed  CAS  Google Scholar 

  • Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF (2008). Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105:15505–10.

    PubMed  CAS  Google Scholar 

  • Miyamoto M, Shimizu Y, Okada K, Kashii Y, Higuchi K, Watanabe A (1998). Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol Immunother 47:47–57.

    PubMed  CAS  Google Scholar 

  • Montgomery AM, Reisfeld RA, Cheresh DA (1994). Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91:8856–60.

    PubMed  CAS  Google Scholar 

  • Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828–31.

    PubMed  CAS  Google Scholar 

  • Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993). Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–80.

    PubMed  CAS  Google Scholar 

  • Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56.

    PubMed  CAS  Google Scholar 

  • Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, Yamamura Y (1981). T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127:412–16.

    PubMed  CAS  Google Scholar 

  • Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J (2008). Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 42:77–84.

    PubMed  CAS  Google Scholar 

  • Naka T, Nishimoto N, Kishimoto T (2002). The paradigm of IL-6: from basic science to medicine. Arthritis Res 4(Suppl 3):S233–S42.

    PubMed  Google Scholar 

  • Nathan C (2002). Points of control in inflammation. Nature 420:846–52.

    PubMed  CAS  Google Scholar 

  • Negus RP, Stamp GW, Hadley J, Balkwill FR (1997). Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C–C chemokines. Am J Pathol 150:1723–34.

    PubMed  CAS  Google Scholar 

  • Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S, Mantovani A, Balkwill FR (1995). The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 95:2391–96.

    PubMed  CAS  Google Scholar 

  • Ness RB, Cottreau C (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–67.

    PubMed  CAS  Google Scholar 

  • Neugut AI, Eisenberg D, Silverstein M, Pulkrabek P, Weinstein IB (1978). Effects of asbestos on epithelioid cell lines. Environ Res 17:256–65.

    PubMed  CAS  Google Scholar 

  • Newhouse ML, Berry G, Wagner JC, Turok ME (1972). A study of the mortality of female asbestos workers. Br J Ind Med 29:134–41.

    PubMed  CAS  Google Scholar 

  • Newhouse ML, Oakes D, Woolley AJ (1985). Mortality of welders and other craftsmen at a shipyard in NE England. Br J Ind Med 42:406–10.

    PubMed  CAS  Google Scholar 

  • Nilsson MB, Langley RR, Fidler IJ (2005). Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–800.

    PubMed  CAS  Google Scholar 

  • O‘Banion MK, Winn VD, Young DA (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89:4888–92.

    PubMed  Google Scholar 

  • Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S (2007). Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 104:12837–42.

    PubMed  CAS  Google Scholar 

  • Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K, Chayama K (2002). Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 102:220–24.

    PubMed  CAS  Google Scholar 

  • Orr MS, O‘Connor PM, Kohn KW (2000). Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 92:987–94.

    PubMed  CAS  Google Scholar 

  • Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–41.

    PubMed  CAS  Google Scholar 

  • Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV (2000). Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10:33–41.

    PubMed  Google Scholar 

  • Peveri P, Walz A, Dewald B, Baggiolini M (1988). A novel neutrophil-activating factor produced by human mononuclear phagocytes. J Exp Med 167:1547–59.

    PubMed  CAS  Google Scholar 

  • Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr., Corey E (2003). Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97:1211–16.

    PubMed  CAS  Google Scholar 

  • Philip M, Rowley DA, Schreiber H (2004). Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–39.

    PubMed  CAS  Google Scholar 

  • Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–66.

    PubMed  CAS  Google Scholar 

  • Pinedo HM, Giaccone G (1995). P-glycoprotein – a marker of cancer-cell behavior. N Engl J Med 333:1417–19.

    PubMed  CAS  Google Scholar 

  • Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA (1994). Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73:1882–88.

    PubMed  CAS  Google Scholar 

  • Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G (2005). Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308:241–53.

    PubMed  CAS  Google Scholar 

  • Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER, Kacinski BM (1993). Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 168:520–27.

    PubMed  CAS  Google Scholar 

  • Rabinovich A, Medina L, Piura B, Segal S, Huleihel M (2007). Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 27:267–72.

    PubMed  CAS  Google Scholar 

  • Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr., Brown EL (1989). Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83:921–26.

    PubMed  CAS  Google Scholar 

  • Risch HA, Howe GR (1995). Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–51.

    PubMed  CAS  Google Scholar 

  • Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, Grizzle WE (2002). Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8:202–09.

    PubMed  CAS  Google Scholar 

  • Rohrschneider LR, Bourette RP, Lioubin MN, Algate PA, Myles GM, Carlberg K (1997). Growth and differentiation signals regulated by the M-CSF receptor. Mol Reprod Dev 46:96–103.

    PubMed  CAS  Google Scholar 

  • Ruoslahti E (1996). Integrin signaling and matrix assembly. Tumour Biol 17:117–24.

    PubMed  CAS  Google Scholar 

  • Ruoslahti E (1999). Fibronectin and its integrin receptors in cancer. Adv Cancer Res 76:1–20.

    PubMed  CAS  Google Scholar 

  • Savill J, Dransfield I, Gregory C, Haslett C (2002). A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965–75.

    PubMed  CAS  Google Scholar 

  • Savill J, Fadok V (2000). Corpse clearance defines the meaning of cell death. Nature 407:784–88.

    PubMed  CAS  Google Scholar 

  • Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr., Ozols RF, Fojo AT, Hamilton TC (1990). Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416–22.

    PubMed  CAS  Google Scholar 

  • Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L, Mantovani A, Melillo G, Sica A (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198:1391–402.

    PubMed  CAS  Google Scholar 

  • Scholl SM, Bascou CH, Mosseri V, Olivares R, Magdelenat H, Dorval T, Palangie T, Validire P, Pouillart P, Stanley ER (1994). Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer 69:342–46.

    PubMed  CAS  Google Scholar 

  • Scotton C, Milliken D, Wilson J, Raju S, Balkwill F (2001a). Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer 85:891–97.

    PubMed  CAS  Google Scholar 

  • Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR (2001b). Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 61:4961–65.

    PubMed  CAS  Google Scholar 

  • Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR (2002). Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62:5930–38.

    PubMed  CAS  Google Scholar 

  • Sehgal PB, Walther Z, Tamm I (1987). Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci USA 84:3663–67.

    PubMed  CAS  Google Scholar 

  • Sharma R, Hook J, Kumar M, Gabra H (2008). Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44:251–56.

    PubMed  Google Scholar 

  • Sherr CJ, Roussel MF, Rettenmier CW (1988). Colony-stimulating factor-1 receptor (c-fms). J Cell Biochem 38:179–87.

    PubMed  CAS  Google Scholar 

  • Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K (2003). Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22:99–105.

    PubMed  CAS  Google Scholar 

  • Silver DL, Naora H, Liu J, Cheng W, Montell DJ (2004). Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64:3550–58.

    PubMed  CAS  Google Scholar 

  • Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ (1994). Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54:3242–47.

    PubMed  CAS  Google Scholar 

  • Sizemore N, Leung S, Stark GR (1999). Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19:4798–805.

    PubMed  CAS  Google Scholar 

  • Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M (2009). Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69:1469–76.

    PubMed  CAS  Google Scholar 

  • Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003). Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL. Nature 425:307–11.

    PubMed  CAS  Google Scholar 

  • Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH (1983). CSF-1 – a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 21:151–59.

    PubMed  CAS  Google Scholar 

  • Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z (2006). Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 66:1744–52.

    PubMed  CAS  Google Scholar 

  • Surowiak P, Materna V, Maciejczyk A, Pudelko M, Markwitz E, Spaczynski M, Dietel M, Zabel M, Lage H (2007). Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450(3):279–85.

    PubMed  CAS  Google Scholar 

  • Szlosarek PW, Balkwill FR (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565–73.

    PubMed  CAS  Google Scholar 

  • Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR (2006). Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5:382–90.

    PubMed  CAS  Google Scholar 

  • Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M (2005). Chemokines in tumor progression and metastasis. Cancer Sci 96:317–22.

    PubMed  CAS  Google Scholar 

  • Toutirais O, Chartier P, Dubois D, Bouet F, Leveque J, Catros-Quemener V, Genetet N (2003). Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 14:246–55.

    PubMed  CAS  Google Scholar 

  • Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK (2009). Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia 11:136–44.

    PubMed  CAS  Google Scholar 

  • Tsan MF (2006). Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16:32–7.

    PubMed  CAS  Google Scholar 

  • Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987–90.

    PubMed  CAS  Google Scholar 

  • Van Gorp T, Amant F, Neven P, Vergote I, Moerman P (2004). Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 18:349–71.

    PubMed  Google Scholar 

  • Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, Luchini L, Crosignani PG (1993). Endometriosis and ovarian cancer. Am J Obstet Gynecol 169:181–2.

    PubMed  CAS  Google Scholar 

  • Wang RF (2001). The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 22:269–76.

    PubMed  Google Scholar 

  • Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM (2005a). Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11:113–22.

    PubMed  CAS  Google Scholar 

  • Wang HY, Peng G, Guo Z, Shevach EM, Wang RF (2005b). Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol 174:2661–70.

    PubMed  CAS  Google Scholar 

  • Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, Yao Z (2005c). Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2:365–72.

    PubMed  CAS  Google Scholar 

  • Watson JM, Berek JS, Martinez-Maza O (1993). Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 49:8–15.

    PubMed  CAS  Google Scholar 

  • Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O (1990). Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50:6959–65.

    PubMed  CAS  Google Scholar 

  • Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006). Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677–88.

    PubMed  CAS  Google Scholar 

  • Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA (2005). Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129:1485–503.

    PubMed  CAS  Google Scholar 

  • Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997–5001.

    PubMed  CAS  Google Scholar 

  • Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–72.

    PubMed  CAS  Google Scholar 

  • Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC (2009). Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 124:1409–15.

    PubMed  CAS  Google Scholar 

  • Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H (2007a). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110:791–800.

    PubMed  CAS  Google Scholar 

  • Xin B, Yokoyama Y, Shigeto T, Mizunuma H (2007b). Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol Oncol Res 13:365–69.

    PubMed  CAS  Google Scholar 

  • Xu L, Pathak PS, Fukumura D (2004). Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 10:701–07.

    PubMed  CAS  Google Scholar 

  • Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC Jr. (1991). Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165:1356–62.

    PubMed  CAS  Google Scholar 

  • Yamamoto Y, Gaynor RB (2001). Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 1:287–96.

    PubMed  CAS  Google Scholar 

  • Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA (2000). Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi’s sarcoma. J Exp Med 191:445–54.

    PubMed  CAS  Google Scholar 

  • Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345–47.

    PubMed  CAS  Google Scholar 

  • Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N (2007). Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 67:871–75.

    PubMed  CAS  Google Scholar 

  • Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T (1982). Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol 128:1296–301.

    PubMed  CAS  Google Scholar 

  • Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19.

    PubMed  CAS  Google Scholar 

  • Zeisler H, Tempfer C, Joura EA, Sliutz G, Koelbl H, Wagner O, Kainz C (1998). Serum interleukin 1 in ovarian cancer patients. Eur J Cancer 34:931–33.

    PubMed  CAS  Google Scholar 

  • Zilberstein A, Ruggieri R, Korn JH, Revel M (1986). Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. Embo J 5:2529–37.

    PubMed  CAS  Google Scholar 

  • Zlotnik A (2006). Chemokines and cancer. Int J Cancer 119:2026–29.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Barts and The London School of Medicine and Dentistry, Institute of Cancer, Centre for Cancer and Inflammation, Queen Mary University of London, London, EC1M 6BQ, UK

    Jermaine Coward & Frances Balkwill

Authors
  1. Jermaine Coward
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frances Balkwill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jermaine Coward .

Editor information

Editors and Affiliations

  1. Royal Marsden Hospital, Drug Development Unit, Institute of Cancer Research, Sutton, SM2 5PT, United Kingdom

    Stan Kaye

  2. , Department of Surgery and Cancer, Imperial College London, London, W12 0NN, United Kingdom

    Robert Brown

  3. , Department of Surgery and Cancer, Imperial College, London, W12 0NN, United Kingdom

    Hani Gabra

  4. , Department of Medicine, Royal Marsden Hospital, London, SW3 6JJ, United Kingdom

    Martin Gore

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Coward, J., Balkwill, F. (2011). Targeting Inflammatory Pathways in Epithelial Ovarian Cancer. In: Kaye, S., Brown, R., Gabra, H., Gore, M. (eds) Emerging Therapeutic Targets in Ovarian Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7216-3_7

Download citation

Publish with us

Policies and ethics

Search

Navigation